The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 1, 2004, Pages 29-36

  Dawson, Adelle ^a   Davies, Justine I ^a   Struthers, Allan D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Aldosterone; Aldosterone escape; Cardiac failure; Eplerenone; Fibrosis; Spironolactone; Vasculopathy

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ACETYLSALICYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; POTASSIUM; SPIRONOLACTONE; VALSARTAN; DRUG DERIVATIVE;

BLOOD VESSEL; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; DRUG TARGETING; ENDOCRINE DISEASE; GYNECOMASTIA; HEART; HEART FAILURE; HORMONE ACTION; HUMAN; HYPERKALEMIA; IMPOTENCE; MASTALGIA; PATHOPHYSIOLOGY; POTASSIUM BLOOD LEVEL; REVIEW; SIDE EFFECT; AUTONOMIC NEUROPATHY; CONGESTIVE HEART FAILURE; HEART MUSCLE FIBROSIS; METABOLIC DISORDER; METABOLISM; PHYSIOLOGY; VASCULAR DISEASE;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; AUTONOMIC NERVOUS SYSTEM DISEASES; ENDOMYOCARDIAL FIBROSIS; HEART FAILURE, CONGESTIVE; HUMANS; SPIRONOLACTONE; VASCULAR DISEASES; WATER-ELECTROLYTE IMBALANCE;

EID: 2342433890     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.1.29     Document Type: Review

References (62)

1. MacFadyen R, Lee AFC, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure. Heart 82, 57-61 (1999).
2. Pitt B, Zannad F, Remme WJ et al. The Randomized Aldactone Evaluation Study Investigators. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. N. Engl. J. Med. 341, 709-717 (1999).
3. Weber KT. Aldosterone in Congestive Heart Failure. N. Engl. J. Med. 345, 1689-1697 (2001).
4. Struthers AD. Aldosterone-induced vasculopathy: a new reversible cause of cardiac death. J. Renin Angiotensin Aldost. Syst. 2, 211-214 (2001).
5. Takeda Y, Miyamori I, Yoneda T et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J. Clin. Endocrinol. Metab. 81, 2797-2800 (1996).
6. Mizuno Y, Yoshimura M, Yasue H et al. Aldosterone Production is Activated in Failing Ventricle in Humans. Circulation 103, 72-77 (2001).
7. --hydroxysteroid dehydrogenase in the human heart. Circulation 92, 175-182 (1995).
8. Golestaneh N, Klein C, Valamanesh F et al. Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton. Biochem. Biophys. Res. Commun. 280, 1300-4306 (2001).
9. Jessup M. Aldosterone Blockade and Heart Failure. N. Engl. J. Med. 348, 1380-1382 (2003).
10. Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am. J. Cardiol. 66, 40D-44D (1990).
11. Vantrimpont P, Rouleau J, Ciampi A et al. Two-year time course and significance of neurohumoral activation in the survival and ventricular enlargement (SAVE). Study. Eur. Heart J. 19, 1552-1563 (1998).
12. Struthers AD. Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure? Br. J. Clin. Pharmacol. 47, 479-482 (1999).
13. Cicoira M, Zanolla L, Franceschini L et al. Relation of Aldosterone "Escape" Despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 89, 403-407 (2002).
14. Lee AFC, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur. J. Heart Fail. 1, 401-406 (1999).
15. Farquharson CAJ, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J. Am. Coll. Cardiol. 39, 767-775 (2002)
16. Urata H, Nishimura H, Ganten D. Mechanisms of angiotensin II formation in humans. Eur. Heart J. 16, 79-85 (1995).
17. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001).
18. Davies J, Struthers A. The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus. J. Renin Angiotensin Aldoster. Syst. 3, 150-155 (2002).
19. Schmidt BM, Montealegre A, Janson CP et al. Short term cardiovascular effects of aldosterone in healthy male volunteers. J. Clin. Endocrinol. Metab. 84, 3528-3533 (1999).
20. Farquharson CAJ, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin. Sci. 103, 425-431 (2002).
21. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dose-dependent regulation of NAD(p)h oxidase expression by angiotensin ii in human endothelial cells: protective effect of angiotensin ii type 1 receptor blockade in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 22, 1845-1851 (2002).
22. Suwaidi JA, Hamasaki S, Higano ST et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101, 948-954 (2000).
23. Duprez DA, De Buyzere ML, Rietzschel ER et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur. Heart J. 19, 1371-1376 (1998).
24. Rietzschel ER, Duprez DA, De Buyzere ML, Clement DL. Inverse relation between aldosterone and venous capacitance in chronically treated congestive heart failure. Am. J. Cardiol. 85, 977-980 (2000).
25. Brown NJ, Kim KS, Chen YQ et al. Synergistic Effect of Adrenal Steroids and Angiotensin II on Plasminogen Activator Inhibitor-1 Production. J. Clin. Endocrinol. Metab. 85, 336-344 (2000).
26. Struthers AD. Evidence for myocardial synthesis of aldosterone producing myocardial fibrosis in man. Clin. Sci. 102, 387 (2002).
27. Satoh M, Nakamura M, Saitoh H et al. Aldosterone synthase (CYP11B2). expression and myocardial fibrosis in the failing human heart. Clin. Sci. (Lond). 102, 381-386 (2002).
28. Diez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 91, 1450-1456 (1995).
29. Klappacher G, Franzen P, Haab D et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am. J. Cardiol. 75, 913-918 (1995).
30. MacFadyen RJ, Barr CS,Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc. Res. 35, 30-34 (1997).
31. Tsutamoto T, Wada A, Maeda K et al. Spironolactone Inhibits the Transcardiac Extraction of Aldosterone in Patients With Congestive Heart Failure. J. Am. Coll. Cardiol. 36, 838-844 (2000).
32. Hayashi M, Tsutamoto T, Wada A et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J. Am. Coll. Cardiol. 38, 1375-1382 (2001).
33. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102, 2700-2706 (2000).
34. Schlaich MP, Schobel HP, Hilgers K, Schmieder RE. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am. J. Cardiol. 85, 1199-1206 (2000).
35. Duprez DA, Bauwens FR, De Buyzere ML et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am. J. Cardiol. 71, 17A-20A (1993).
36. Delles C, Schmidt BMW, Müller HJ et al. Functional Relevance of Aldosterone for the Determination of Left Ventricular Mass. Am. J. Cardiol. 91, 297-301 (2003).
37. Redfield M, Jacobsen S, Burnett J et al. Burden of Systolic and Diastolic Ventricular Dysfunction in the Community. Appreciating the Scope of the Heart Failure Epidemic. JAMA 289, 194-202 (2003).
38. Fagard R, Lijnen P, Petrov V. Opposite asociations of circulating aldosterone and ANP with left ventricular diastolic function in essential hypertension. J. Hum. Hypertens. 12, 195-202 (1998).
39. Bashir Y, Sneddon JF, Staunton HA et al. Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. Am. J. Cardiol. 72, 1156-1162 (1993).
40. Zehender M, Meinertz T, Faber T et al. Antiarrhythmic effects of increasing the daily intake of magnesium and potassium in patients with frequent ventricular arrhythmias. Magnesium in Cardiac Arrhythmias (MAGICA). Investigators. J. Am. Coll. Cardiol. 29, 1028-1034 (1997).
41. Gottheb S, Fischer M, Pressel M et al. Effects of intravenous magnesium sulphate on arrhythmias in patients with congestive heart failure. Am. Heart. J. 125, 1645-1650 (1993).
42. Ascherio A, Rimm EB, Hernan MA et al. Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation 98, 1198-1204 (1998).
43. Tsuji H, Larson MG, Venditti FJ Jr. et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 94, 2850-2855 (1996).
44. Zuanetti G, Neilson JM, Latini R et al. Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. Circulation 94, 432-436 (1996).
45. La Rovere MT, Bigger JT Jr. Marcus FI et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction). Investigators. Lancet 351, 478-484 (1998).
46. Barr CS, Lang C, Hanson J et al. Effects of Adding Spironolactone to an Angiotensin-Converting Enzyme Inhibitor in Chronic Congestive Heart Failure Secondary to Coronary Artery Disease. Am. J. Cardiol. 76, 1259-1265 (1995).
47. Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin. Sci. (Colch.) 95, 687-692 (1998).
48. Moser D, Stevenson W, Woo M, Stevenson L. Timing of sudden death in patients with heart failure. J. Am. Coll. Cardiol. 24, 963-967 (1994).
49. Chowdhary S, Townend JN. Role of nitric oxide in the regulation of cardiovascular autonomic control. Clin. Sci. (Colch.) 97, 5-17 (1999).
50. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101, 594-597 (2000).
51. Pitt B, Remme W, Zannad F et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N. Engl. J. Med. 348, 1309-1321 (2003).
52. Delyani J, Rocha R, Cook C et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc. Drug Rev. 19, 185-200 (2001).
53. Yalan A, Dincer M, Aslan V, Gulbas Z. Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press. Res. 25, 260-264 (2002).
54. Hayashi M, Tsutamoto T, Wada A et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107, 2559-2565 (2003).
55. Ramires FJA, Mansur A, Coelho O et al. Effect of Spironolactone on Ventricular Arrhythmias in Congestive Heart Failure Secondary to Idiopathic Dilated or to Ischemic Cardiomyopathy. Am. J. Cardiol. 85, 1207-1211 (2000).
56. Yee KM, Pringle SD, Struthers AD. Circadian Variation in the Effects of Aldosterone Blockade on Heart Rate Variability and QT Dispersion in Congestive Heart Failure. J. Am. Coll. Cardiol. 37, 1800-4807 (2001).
57. Degre S, Derry JM, Unger P et al. Effects of spironolactone-altizide on left ventricular hypertrophy. Acta Cardiol. 53, 261-267 (1998).
58. Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens. Res. 25, 837-842 (2002).
59. Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol. 37, 1228-1233 (2001).
60. Verdecchia P, Schillaci G, Borgioni C et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97, 48-54 (1998).
61. Brown NJ. Eplerenone. Cardiovascular Protection. Circulation 107, 2512-2518 (2003).
62. Williams E, Miller J. Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session. J. Am. Coll. Cardiol. 40, 1-18 (2002).